5月25日至29日，第二十届中国西部国际博览会在四川成都举行，国内外3000余家企业参展。作为中国 对外开放的重要窗口，本届西博会共签约投资合作项目416个，投资金额3543亿元，推出对外招商投资 合作项目超2200个，投资金额超3.7万亿元，向世界充分展示了中国西部的发展潜力和投资吸引力，为 西部地区高质量发展注入新动能。 投资前景受瞩目 近年来，西部地区充分发挥特色优势，融入全球产业链供应链，在科技创新、产业升级、对外贸易拓展 等方面取得了丰硕成果。西博会，正是展示成果、释放机遇的最佳平台。 青海省近年来在生态文明高地建设、产业"四地"发展、绿色算力产业推进等方面取得了可喜的成 就。"青海省组织了20余家优质特色企业亮相本届西博会，旨在进一步拓展消费市场，助力'青字号'产 品提升市场影响力。"青海省工业和信息化厅经济协作处副处长马顺祥介绍。 "展台展示的超高剂量率电子射线放射治疗系统（e-Flash）通过在极短时间内释放超高剂量率的电子射 线对肿瘤进行治疗，大幅提升癌细胞杀伤效率，有效缩短放疗时间。"中玖闪光医疗科技有限公司市场 专员张裕芊向记者介绍。环视绵阳馆，小型核动力装置模型、花瓣加速器模型等20余 ...

来源：中国新闻网 中新网上海5月31日电 (记者 陈静)记者31日获悉，正在上海举行的第十九届东方心脏病学会议 (OCC2025)(简称：东方会)发布"观心大模型CardioMind"(简称："观心大模型")。 "观心大模型CardioMind"在东方会上发布。(东方会组委会供图) 作为本次大会主席，葛均波院士表示，东方会秉持"开放、创新、合作"的宗旨，近年来尤其关注人工智 能在心血管领域的应用，展示了前瞻性的洞察力。上海市卫生健康委党组书记、主任闻大翔指出，东方 会将大数据应用、人工智能赋能、数字疗法等新技术融入学术交流，体现了促进心血管疾病防治高质量 发展的担当。 中国科学院院士顾东风教授展望了人工智能在流行病学研究中的革命性应用，通过可穿戴设备，整合个 人生活方式、营养、体力活动等多维度数据，有望超越传统调查方法，丰富个人健康档案，建立更精准 的个体化预测模型，并为公共卫生政策制定提供科学依据。 智能导管室的现场演示成为东方会的一个亮点。(东方会组委会供图) 智能导管室的现场演示成为本次大会的又一亮点，复旦大学附属中山医院心内科李晨光教授、陆浩教授 等展示了AI在复杂冠脉介入手术中的辅助作用。记者看到， ...

罗氏制药中东地区负责人奥法特·贝罗；信诺医疗保健中东和非洲（不含沙特）首席执行官利亚·科特里尔；以及 January AI公司创始人兼首席执行官诺辛·哈希米（从左到右）。 图片来源：Iman Al-dabbagh—Fortune 据预测，到本世纪中叶，全球糖尿病患者将达13亿人，若计入糖尿病前期人群，这一数字将攀升至50 亿。当前，人工智能技术能够帮助糖尿病患者实时掌握食物成分及潜在血糖反应；未来，人工智能还将 助力预测患者可能罹患的病症，并指导采取早期干预措施。 在利雅得召开的《财富》"全球最具影响力商界女性"峰会上，医疗行业领袖们指出，人工智能将在防治 糖尿病相关疾病方面扮演日益重要的角色，尤其是存在大量生活方式相关糖尿病患者的中东等地区。 人工智能健康平台January AI创始人兼首席执行官诺辛·哈希米指出："数据触目惊心。至2050年，全球 糖尿病患者将达到13亿，而糖尿病前期人群规模约为这个数字的三倍。……这意味着超50亿人将出现胰 岛素抵抗，占全球半数人口。"该平台通过人工智能技术提供个性化营养建议与血糖监测分析。 信诺医疗保健（Cigna Healthcare）中东及非洲（不含沙特）首席执行官 ...

Group 1 - The core point of the news is that Cangnan State-owned Assets is providing substantial financial support to Sichuang Medical Technology Co., Ltd. (思创医惠) through a loan of up to 630 million RMB, which signifies strong backing for the company's sustainable development [1][2] - The financial assistance from Cangnan Shanhai Industrial Group Co., Ltd. is based on mutual agreement and will be calculated at the one-year Loan Prime Rate (LPR) without requiring any guarantees or collateral from Sichuang Medical [1] - This financial support reflects Cangnan State-owned Assets' confidence in Sichuang Medical's future development and aims to alleviate the company's short-term funding pressures while supporting its long-term growth [2] Group 2 - Cangnan State-owned Assets has extended its involvement with Sichuang Medical from asset-level support to equity and control, with plans for Cangnan Jian Investment to acquire a significant stake in the company [2] - The recent financial aid is part of a broader strategy by Cangnan State-owned Assets, which includes asset disposal, subsidiary equity acquisitions, and control transfer, to create a comprehensive support system for Sichuang Medical [2]

Group 1 - The company, Jianerkang Medical Technology Co., Ltd., will hold its 2024 annual performance briefing on June 5, 2025, from 10:00 to 11:00 AM [2][3] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [3][4] - Key personnel attending the meeting include the Chairman, General Manager, Secretary of the Board, Chief Financial Officer, Independent Director, and Sponsor Representative [3] Group 2 - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center website and will have the opportunity to ask questions [4] - Questions can be submitted from May 28, 2025, to June 4, 2025, before 4:00 PM through the website or via the company's email [4] - After the briefing, investors can view the meeting's details and main content on the Shanghai Stock Exchange Roadshow Center [4]

一、AI的企业应用仍处于初期阶段 人工智能的2C应用进展很快，2024年美国居民生成式AI的渗透率已达39.6% （来源：圣路易斯联储） 。然 而，当前的模型厂商还热衷于评分打榜、技术炫耀，企业应用尚处于早期阶段。迫切需要找到丰富落地 场景，加快推进AI和各行各业的深度融合。 国联证券对A股上市公司财报中提及AI的情况进行了梳理，近年提及数量迅速增加，从2020年的172家 上升至2023年的超过1200家，然而在所有A股上市公司的占比仍然不高，2023年还不到20%。根据国家 经济研究局 （NBER） 数据，截止2024年2月，美国AI企业采用率仅有5.4%。根据欧盟统计局数据，2024 年欧盟各国AI企业普及率在3.1%-27.6%之间，总体为13.5%。如下图所示。各国对问题的定义和调研方 法有所不同，以上数据不能简单横向比较，但都反映出AI的企业应用还处于初期阶段。 图 2024年欧盟的AI企业普及率 来源：根据欧盟统计局数据整理，2025 闫德利 腾讯研究院资深专家 二、信息密度越高，AI应用越易越深 AI的企业应用具有明显的行业差异，它与信息密度有关。大体是信息密度越高，AI应用越容易越深入； 信 ...

Core Viewpoint - The company is actively expanding its business in HVLS fans, artificial intelligence, and smart governance, while facing challenges in revenue and profitability in the recent quarter [2][8]. Group 1: HVLS Fan Business - The HVLS fan business is the company's main revenue source, achieving a revenue of 244 million yuan in 2024 with a gross margin of 36.95% [2]. - The company holds a leading position in the domestic HVLS fan industry and aims to increase its overseas market share, which currently accounts for 23.31% of total revenue [2]. Group 2: Artificial Intelligence Initiatives - The company is leveraging its joint venture, Henan Yuzhi Kaile Intelligent Technology Co., Ltd., to advance AI applications in smart office, smart travel, and smart healthcare [3]. - The AI solutions provided are designed to ensure data security and compliance while enhancing operational efficiency [3]. Group 3: Smart Driving Collaboration - A cooperation agreement was signed with the Henan Provincial Automotive Industry Investment Group to promote digital and intelligent upgrades in the automotive sector, focusing on autonomous driving technology [4]. - The collaboration aims to develop technologies related to unmanned vehicles and logistics [4]. Group 4: Smart Governance Developments - In April 2025, the company launched a large model government integrated machine in collaboration with People's Daily Online, enhancing its offerings in smart governance [5]. - The "Deep Language Future" smart governance machine is designed for local deployment and ensures data security and compliance with government regulations [6]. Group 5: AI Medical Solutions - The AI medical segment focuses on providing various solutions for different medical applications, including smart hospital renovations and AI-assisted research platforms [7]. - Collaborations with major hospitals and health institutions are underway to enhance clinical and research capabilities using AI technologies [8]. Group 6: Financial Performance - In Q1 2025, the company reported a main revenue of 37.91 million yuan, a year-on-year decrease of 20.13%, while the net profit attributable to shareholders was -5.17 million yuan, an increase of 44.54% year-on-year [8]. - The company’s debt ratio stands at 16.59%, with investment income of 1.17 million yuan and a gross margin of 41.76% [8].

证券代码：300253 证券简称：卫宁健康 公告编号：2025-046 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金到位情况 卫宁健康科技集团股份有限公司（以下简称"公司"）经中国证 券监督管理委员会《关于同意卫宁健康科技集团股份有限公司向不特 定对象发行可转换公司债券注册的批复》 （证监许可［2021］311 号） 核准，获准向不特定对象发行可转换公司债券 970.2650 万张，每张 面 值 为 人 民 币 100 元 ， 按 面 值 发 行 ， 募 集 资 金 总 额 为 人 民 币 实际募集资金净额为人民币 961,209,622.64 元。 容诚会计师事务所（特殊普通合伙）已对公司向不特定对象发行可转 换公司债券的募集资金到位情况进行了审验，并于 2021 年 3 月 23 日 出具了"容诚验字2021200Z0016 号" 下简称"国泰君安"）分别与宁波银行股份有限公司上海黄浦支行、 上海银行股份有限公司浦西支行（以下简称"上海银行浦西支行"） 中国民生银行股 ...

Group 1 - NuraNavX, a brain science AI company, recently completed a multi-million yuan angel round financing led by K2 Venture Partners, with funds aimed at market promotion and further R&D of AI brain connectomics products [1] - The company's AI-based individualized brain network mapping, which can be understood as a "GPS for the brain," reveals how different brain regions connect, crucial for understanding complex brain diseases [1] - NuraNavX divides each patient's brain into 379 unique regions based on MRI data and has identified over 20 important brain functional networks, enabling personalized brain network maps for surgical protection and targeted treatment of central nervous system diseases like depression and anxiety [1] Group 2 - The company has established self-operated neuroregulation clinics in Shenzhen and Shanghai, providing treatments for various conditions including depression, anxiety, insomnia, and schizophrenia [2] - In addition to medical-grade products and services, NuraNavX's AI brain connectomics software supports researchers in brain science and has developed consumer-level brain health assessment reports to identify potential risks early [2]

2025.05. 26 本文字数：4795，阅读时长大约8分钟 作者 | 第一财经 钱童心 人工智能正在将临床诊疗方式从经验医学转变为由数据驱动。从影像识别、病理分析到手术机器人， AI的发展正在推动个性化治疗的发展，掀起一场"智能医学"的变革。 但这并不意味着我们不再需要有经验的医生，而是在AI的赋能下，更多的年轻医生利用技术也能提升 诊疗水平，整个医疗价值链也将被重塑。 AI能精准诊断冠心病吗 人工智能等新技术的飞速发展，正在悄然改变社会和人们的生活，在医学领域亦是如此，新技术为临 床诊疗和科学研究带来了新视野，也已经产生了不少突破性的成果。 "原本依赖医生经验与感觉判断的部分，在智能化与数字化的辅助下，边界也没有那么绝对了。"中国 科学院院士、复旦大学附属中山医院樊嘉教授在《在科技变革中，成为不可替代的你》一文中写道。 樊嘉表示，数字孪生医生已逐渐成为中山医院医疗团队中的重要成员——这些"数字分身"会对"生物 人医生"原型进行建模与仿真，而不仅仅是知识结构的复制和经验叠加。 他告诉第一财经记者，这些"数字医生"有些已经成形，例如"小葛"医生和"小白"医生，分别代表了中 山医院心内科葛均波院士及呼吸科白春 ...